CytoMed Therapeutics, a Singapore-based biopharmaceutical company, announced the successful completion of dose level 1 in its first-in-human Phase I clinical trial (ANGELICA Trial) for CTM-N2D, an allogeneic cell therapy for advanced cancers. Four late-stage cancer patients participated, and the trial will proceed to dose level 2 in Q3 2025. The trial aims to evaluate the safety and tolerability of CTM-N2D across a range of solid and blood cancers.
This successful completion of the first dose level is a crucial step in advancing a potentially more accessible and effective cancer treatment. CTM-N2D leverages gamma delta T cells from healthy donors, eliminating the need for donor-patient matching required in conventional CAR-T therapies. This “off-the-shelf” approach could significantly reduce treatment costs and waiting times, potentially benefiting a broader patient population. Successful clinical development could revolutionize cancer care by making personalized immunotherapy readily available.
The ANGELICA Trial focuses on evaluating the safety and tolerability of escalating doses of CTM-N2D. The therapy targets NKG2DL, a protein frequently overexpressed in various cancers. Because CTM-N2D utilizes allogeneic cells, it offers a significant logistical advantage over autologous CAR-T cell therapies, which rely on modifying a patient’s own cells.
The positive initial results from the ANGELICA Trial pave the way for continued clinical investigation of CTM-N2D. Further data from subsequent dose levels and expansion cohorts will be critical for assessing the therapy’s efficacy and confirming its potential to offer a new treatment paradigm for patients with advanced cancers. This progress signifies a potential shift towards more readily available and potentially cost-effective cell therapies in the oncology landscape.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
